GE HEALTHCARE TECHNOLOGIES INC.
At today's price, GE HEALTHCARE TECHNOLOGIES INC. (GEHC) is priced for +7.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- GE HealthCare is an installed-base medtech franchise: imaging systems sold once, then serviced and supplied for a decade-plus, with a record $21.8 billion backlog and a roughly 18% trailing ROE the snapshot multiples understate. - The valuation methods disagree: only the sector-multiple relative frame (near $92) supports the $61.60 price, while earnings-power value (near $46) and most conservative frames land a quarter or more below it (blended landing near $54). - The near-term risk is margin
Is GEHC overvalued? See what's priced in →
1,229 institutional managers reported holding GEHC in 13F filings for the quarter ended 2026-03-31. Together they hold about 83% of the company; the top 10 hold 48%. 102 opened new positions that quarter. Held by Vanguard Group, BlackRock, Dodge & Cox, among others. On the short side, 15.6M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GEHC's share count is about flat over the past five years ($300.00M of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (3 and counting), raised 2 years straight; the current rate is $0.14 a share annually. Cash returned over the past three years: $162.00M in dividends and $300.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at GEHC over the trailing three years: 2024: 1 buy totaling $101k; 2026: 1 buy totaling $642k. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GEHC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-26 | -4.0% | -11.8% |
| 2023-11-01 | +8.1% | +11.5% |
| 2024-02-07 | +11.5% | +4.3% |
| 2024-05-01 | -12.0% | -1.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GEHC's latest 8-K filings: 2026-05-11 (items 5.07, 8.01); 2026-04-29 (items 2.02, 9.01); 2026-03-17 (items 5.02, 7.01, 9.01); 2026-02-27 (items 1.01, 1.02, 2.03, 9.01); 2026-02-04 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.